BB Biotech AG (FRA:BBZA) Gross-Profit-to-Asset % : 17.39% (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is BB Biotech AG Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. BB Biotech AG's annualized Gross Profit for the quarter that ended in Dec. 2023 was €471.52 Mil. BB Biotech AG's average Total Assets over the quarter that ended in Dec. 2023 was €2,710.94 Mil. Therefore, BB Biotech AG's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 17.39%.

BB Biotech AG Gross-Profit-to-Asset % Historical Data

The historical data trend for BB Biotech AG's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BB Biotech AG Gross-Profit-to-Asset % Chart

BB Biotech AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

20.95

18.69

-10.62

-10.79

-7.19

BB Biotech AG Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Dec17	Dec18	Dec19	Dec20	Mar21	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															-4.40	-35.62	-0.73	-6.44	17.39

Competitive Comparison of BB Biotech AG's Gross-Profit-to-Asset %

For the Biotechnology subindustry, BB Biotech AG's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BB Biotech AG's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BB Biotech AG's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where BB Biotech AG's Gross-Profit-to-Asset % falls into.

BB Biotech AG Gross-Profit-to-Asset % Calculation

BB Biotech AG's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	-211.613	/	( (3094.031	+	2796.335)	/ 2 )
	=	-211.613	/	2945.183
	=	-7.19 %

BB Biotech AG's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	471.52	/	( (2625.538	+	2796.335)	/ 2 )
	=	471.52	/	2710.9365
	=	17.39 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

BB Biotech AG Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of BB Biotech AG's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

BB Biotech AG (FRA:BBZA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BB Biotech AG (FRA:BBZA) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

BIONz:UK BBZA:Germany BION:Switzerland

Address

Schwertstrasse 6, Schaffhausen, CHE, CH-8200

Website

https://www.bbbiotech.com

BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market and is one of the largest investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. BB Biotech follows a strategy of carefully screening and selecting biotechnology firms with a long-term time horizon and having established products in the marketplace. Geographically it earns key revenue from the Netherlands.

BB Biotech AG (FRA:BBZA) Headlines

No Headlines